MetaCap

Design Therapeutics (DSGN) vs Geron (GERN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Design Therapeutics (DSGN) has outperformed Geron (GERN) over the past year, gaining 8.0% versus a loss of 22.3%. Over five years, GERN leads with a -40.8% price change compared with -49.3% for DSGN. Design Therapeutics is the larger company by market cap ($577.6 million vs $560.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DSGN+8.02%GERN-22.26%
+97%+34%-28%
Nov 21, 20251 yearNov 20, 2026
DSGN-56.02%GERN-43.46%
+232%+63%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DSGN versus GERN key metrics
MetricDSGNGERN
Share price$9.02$0.8707
Market cap$577.61M$560.94M
1-day change-3.22%-4.63%
YTD return-3.84%-34.04%
1-year return+8.02%-22.26%
5-year return-49.27%-40.77%
Forward P/E—9.67
EPS (TTM)$-1.20$-0.08
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Net income (latest FY)$-69.79M$-83.50M
52-week high$17.25$2.01
52-week low$8.21$0.84
Distance from 52-week high-47.71%-56.68%
Analyst consensusstrong_buybuy
Avg. price target upside+139.14%+301.98%
Average volume554.69K13.05M
Shares outstanding64.04M644.24M
Employees60258
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DSGN has outperformed GERN by 30.3 percentage points over the past year.

About Design Therapeutics

DSGN stock →

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees

About Geron

GERN stock →

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML.

Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees

DSGN vs GERN FAQ

Which is bigger, Design Therapeutics or Geron?

Design Therapeutics (DSGN) is larger, with a market capitalization of $577.61M compared with $560.94M for Geron (GERN).

Which stock has performed better over the past year, DSGN or GERN?

DSGN returned +8.02% over the past 12 months, compared with -22.26% for GERN (price return, excluding dividends). Past performance does not predict future results.

Are Design Therapeutics and Geron in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons